Asilomar2: An Idea Whose Time Has Come

Several announcements on biotechnology research have made the front pages of the country's major newspapers over the past few months. Stories have ranged from gene therapy on a fetus, to the highly competitive race to crack the human gene code, to an attempt to transfer genes from the egg of an infertile woman into the egg of another woman in the hopes of achieving a viable pregnancy. As with the announcement two years ago of the cloning of an adult ewe in Scotland, these reports cause feelings

Written byGeorge Davatelis
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Several announcements on biotechnology research have made the front pages of the country's major newspapers over the past few months. Stories have ranged from gene therapy on a fetus, to the highly competitive race to crack the human gene code, to an attempt to transfer genes from the egg of an infertile woman into the egg of another woman in the hopes of achieving a viable pregnancy. As with the announcement two years ago of the cloning of an adult ewe in Scotland, these reports cause feelings of excitement in some and fear in others--and for most of us, both.

The recent developments have once again sparked concern among segments of scientific and public communities over the ethics of biotechnology and genetic manipulation, particularly as it relates to human cloning. The news revived long-standing debates among scientists, theologians, ethicists, policymakers, and the lay public over the applications of breakthrough advances ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies